×
About 54,606 results

ALLMedicine™ Systemic Lupus Erythematosus Center

Research & Reviews  25,921 results

Novel signatures associated with systemic lupus erythematosus clinical response to IFN-...
https://doi.org/10.1177/0961203321995576
Lupus Seridi L, Cesaroni M et. al.

Feb 25th, 2021 - We aimed to identify transcriptional gene signatures predictive of clinical response, for pharmacodynamic evaluation, and to provide mechanistic insight into JNJ-55920839, a human IgG1κ neutralizing mAb targeting IFN-α/IFN-ω, in participants with ...

Smoking exposure in pack-years predicts cutaneous manifestations and damage in systemic...
https://doi.org/10.1177/0961203321995257
Lupus Ezeh N, McKown T et. al.

Feb 25th, 2021 - To examine the impact of cumulative smoking in pack-years on systemic lupus erythematosus (SLE) cutaneous manifestations and damage. Our cohort study included 632 adult SLE patients at an academic center, meeting 1997 ACR or 2012 SLICC classificat...

Cotrimoxazole prophylaxis prevents major infective episodes in patients with systemic l...
https://doi.org/10.1177/0961203321995238
Lupus Ganu SA, Mathew AJ et. al.

Feb 25th, 2021 - Prophylactic trimethoprim-sulfamethoxazole (TMP-SMX) prevents pneumocystis jirovecii infection in SLE on immunosuppression. Its role in preventing other major infections in immuno suppressed SLE patients is unknown. A non-concurrent cohort study w...

Psychosis in Systemic Lupus Erythematosus (SLE): 40-year experience of a specialist cen...
https://doi.org/10.1093/rheumatology/keab160
Rheumatology (Oxford, England); Abrol E, Coutinho E et. al.

Feb 25th, 2021 - The long-term outcome of psychosis in association with Systemic Lupus Erythematosus (SLE) has been insufficiently characterised. We used a specialist centre cohort of patients with SLE and psychosis to investigate their clinical outcome and phenot...

"It is good to have a target in mind": Qualitative views of patients and parents inform...
https://doi.org/10.1093/rheumatology/keab173
Rheumatology (Oxford, England); Smith EMD, Gorst SL et. al.

Feb 25th, 2021 - We sought to explore patient and parental views on treatment targets, outcome measures and study designs being considered for a future juvenile-onset systemic lupus erythematosus (JSLE) treat to target (T2T) study. Topic guided, semi-structured in...

see more →

Guidelines  87 results

ACR Convergence 2020: Study Data for Lupus & Rheumatoid Arthritis
https://www.the-rheumatologist.org/article/acr-convergence-2020-study-data-for-lupus-rheumatoid-arthritis/
The Rheumatologist; Hickman RJ.

Nov 8th, 2020 - At the annual meeting’s second Plenary Session, Saturday, Nov. 7, speakers highlighted phase 2 results of a potential new biologic for systemic lupus erythematosus (SLE), as well as data on remission maintenance in rheumatoid arthritis (RA) after ...

Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20 years of drug safety surveillance reports
https://pubmed.ncbi.nlm.nih.gov/33154498/
Scientific Reports; Cohen IV, Makunts T et. al.

Nov 4th, 2020 - Chloroquine (CQ) and hydroxychloroquine (HCQ) are on the World Health Organization's List of Essential Medications for treating non-resistant malaria, rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). In addition, both drugs are cu...

Do Menopause and Aging Affect the Onset and Progression of Rheumatoid Arthritis and Systemic Lupus Erythematosus?
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7557711/
Cureus Shah L

Oct 11th, 2020 - Rheumatoid arthritis and systemic lupus erythematosus (SLE) are autoimmune diseases that are commonly seen in the female population. Rheumatoid arthritis mainly consists of distal symmetrical deforming polyarthritis. SLE patients have immune compl...

Fasting Triglycerides & Glucose Index: A Useful Screening Test for Assessing Insulin Resistance in Patients Diagnosed with Rheumatoid Arthritis & Systemic Lupus Erythematosus
https://dmsjournal.biomedcentral.com/articles/10.1186/s13098-019-0495-x
Diabetology & Metabolic Syndrome; Contreras-Haro B,et al

Nov 26th, 2019 - Insulin resistance (IR) is frequently observed in patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). In clinical practice, IR assessment is limited to a low proportion of patients due to cost and equipment and technical...

Sjögren’s Syndrome in Systemic Lupus Erythematosus - a Subset Characterized by a Systemic Inflammatory State
http://www.jrheum.org/content/early/2019/09/11/jrheum.190250
J Rheumatology; Ruacho G,et al

Sep 20th, 2019 - Secondary Sjögren’s syndrome (SLE-sSS) is an often-neglected subset of patients with Systemic lupus erythematosus (SLE). Furthermore, primary Sjögren’s syndrome overlaps and can be difficult to delineate from SLE. To shed light on the SLE-sSS subs...

see more →

Drugs  27 results see all →

Clinicaltrials.gov  26,883 results

Novel signatures associated with systemic lupus erythematosus clinical response to IFN-...
https://doi.org/10.1177/0961203321995576
Lupus Seridi L, Cesaroni M et. al.

Feb 25th, 2021 - We aimed to identify transcriptional gene signatures predictive of clinical response, for pharmacodynamic evaluation, and to provide mechanistic insight into JNJ-55920839, a human IgG1κ neutralizing mAb targeting IFN-α/IFN-ω, in participants with ...

Smoking exposure in pack-years predicts cutaneous manifestations and damage in systemic...
https://doi.org/10.1177/0961203321995257
Lupus Ezeh N, McKown T et. al.

Feb 25th, 2021 - To examine the impact of cumulative smoking in pack-years on systemic lupus erythematosus (SLE) cutaneous manifestations and damage. Our cohort study included 632 adult SLE patients at an academic center, meeting 1997 ACR or 2012 SLICC classificat...

Cotrimoxazole prophylaxis prevents major infective episodes in patients with systemic l...
https://doi.org/10.1177/0961203321995238
Lupus Ganu SA, Mathew AJ et. al.

Feb 25th, 2021 - Prophylactic trimethoprim-sulfamethoxazole (TMP-SMX) prevents pneumocystis jirovecii infection in SLE on immunosuppression. Its role in preventing other major infections in immuno suppressed SLE patients is unknown. A non-concurrent cohort study w...

Psychosis in Systemic Lupus Erythematosus (SLE): 40-year experience of a specialist cen...
https://doi.org/10.1093/rheumatology/keab160
Rheumatology (Oxford, England); Abrol E, Coutinho E et. al.

Feb 25th, 2021 - The long-term outcome of psychosis in association with Systemic Lupus Erythematosus (SLE) has been insufficiently characterised. We used a specialist centre cohort of patients with SLE and psychosis to investigate their clinical outcome and phenot...

"It is good to have a target in mind": Qualitative views of patients and parents inform...
https://doi.org/10.1093/rheumatology/keab173
Rheumatology (Oxford, England); Smith EMD, Gorst SL et. al.

Feb 25th, 2021 - We sought to explore patient and parental views on treatment targets, outcome measures and study designs being considered for a future juvenile-onset systemic lupus erythematosus (JSLE) treat to target (T2T) study. Topic guided, semi-structured in...

see more →

News  1,673 results

Meta-Analysis Finds Much Less Lupus Than Expected
https://www.medscape.com/viewarticle/945116

Feb 1st, 2021 - The prevalence of systemic lupus erythematosus (SLE) appears to be much lower than previously believed and may pose "a potential risk to research funding for the disease," according to results of a meta-analysis involving a network of population-b...

High Hydroxychloroquine Blood Level May Lower Thrombosis Risk in Lupus
https://www.medscape.com/viewarticle/943726

Jan 6th, 2021 - Maintaining an average hydroxychloroquine whole blood level above 1,068 ng/mL significantly reduced the risk of thrombosis in adults with systemic lupus erythematosus, based on data from 739 patients. Hydroxychloroquine (HCQ) is a common treatment...

FDA Expands Belimumab Indication to Adults With Lupus Nephritis
https://www.medscape.com/viewarticle/942894

Dec 17th, 2020 - The US Food and Drug Administration (FDA) has expanded the indication for belimumab (Benlysta) to adults with active lupus nephritis who are receiving standard therapy. Roughly 40% of patients with systemic lupus erythematosus (SLE) develop lupus ...

Worse AMI Outcomes for Lupus, Systemic Sclerosis Patients
https://www.medscape.com/viewarticle/942688

Dec 15th, 2020 - NEW YORK (Reuters Health) - Patients with systemic lupus erythematosus (SLE) are less likely to receive invasive treatment for acute myocardial infarction (AMI) and have worse AMI outcomes than do patients without autoimmune rheumatic disease (AIR...

High-Need, High-Cost Lupus Patients Described for First Time
https://www.medscape.com/viewarticle/942712

Dec 15th, 2020 - A small group of patients with systemic lupus erythematosus (SLE) who have high costs and needs and frequent hospitalizations can be identified through a shared set of sociodemographic characteristics and risk factors that distinguish them from ot...

see more →

Patient Education  15 results see all →